Moléculas PACAP, GEPANT e DITANS são destaques nas atuais fronteiras da cefaleia O XIII Congresso Paulista de Neurologia, promovido pela Associação...
XIII Congresso Paulista de Neurologia: Novos alvos terapêuticos para migrânea
Escrito por: MDHealth em 31 de maio de 2021
4 min de leitura
Referências
XIII Congresso Paulista de Neurologia, 28 de Maio de 2021, Sala 1 – Cefaleia I – Dr Caio Simioni, Dr Marcelo C. Ciciarelli, Dra Thais Villa.
Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019 Oct;39(11):1343-1357. doi: 10.1177/0333102419864132. Epub 2019 Aug 21. PMID: 31433669; PMCID: PMC6779019.
Loo LS, Ailani J, Schim J, Baygani S, Hundemer HP, Port M, Krege JH. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019 Jul 24;20(1):84. doi: 10.1186/s10194-019-1032-x. PMID: 31340760; PMCID: PMC6734212.
